Hepatic Manifestations in Juvenile Systemic Lupus Erythematosus

Author(s): Mortada H. El-Shabrawi, Mona I. Farrag

Journal Name: Recent Patents on Inflammation & Allergy Drug Discovery
Continued as Recent Advances in Inflammation & Allergy Drug Discovery

Volume 8 , Issue 1 , 2014


Juvenile systemic lupus erythematosus (JSLE) is a chronic autoimmune disease characterized by multisystem involvement and diverse clinical and serological manifestations. Clinically significant hepatic disease is generally regarded as unusual in JSLE, but many studies have showed that hepatic disease may be more common in SLE than was usually thought. Hepatic disease does not cause significant morbidity and mortality, but subclinical liver involvement is common. One of the hepatic disorders associated with JSLE is autoimmune hepatitis (AIH). The precise etiology of AIH and JSLE remains unknown, however both AIH and JSLE are associated with antinuclear antibody (ANA) and multisystem disease manifestations. A shared immunologic response and genetic predisposition were suggested. Recently, new approaches for treatment of SLE and recent patents that could develop into novel therapeutic agents in clinical management of SLE have been proposed. An array of promising new therapies is currently emerging or being developed including B-cell depletion therapies, agents targeting B-cell survival factors, blockade of T-cell co-stimulation and present review, we will also report the case of a 12-year old girl who developed JSLE four years after her preliminary diagnosis with AIH.

Keywords: Autoimmune hepatitis, hepatic disorders, novel therapies, systemic lupus erythematosus.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2014
Published on: 21 February, 2014
Page: [36 - 40]
Pages: 5
DOI: 10.2174/1872213X07666131229110501

Article Metrics

PDF: 60